Month: July 2020

TORONTO, July 08, 2020 (GLOBE NEWSWIRE) — Dundee Precious Metals Inc. (TSX: DPM) (“DPM” or “the Company”) announced strong preliminary production results from both of its mines and the smelter for the three and six months ended June 30, 2020. The Company is on track to meet its previously issued guidance for 2020 at each of its operations.“We continue to prioritize the health and safety of our workforce and to provide support in our local communities as we proactively manage the circumstances related to the global COVID-19 pandemic,” said David Rae, President and CEO. “Despite these challenges, we delivered another exceptional quarter of production results at each of our three operations and continue to demonstrate the significant potential of our portfolio in 2020.”Production HighlightsPreliminary results for the second quarter...

TAMPA, Fla., July 08, 2020 (GLOBE NEWSWIRE) — Kforce Inc. (NASDAQ: KFRC), a provider of professional staffing services and solutions, on Monday, August 10, 2020 will release second quarter results post-market and host a conference call to discuss the results.  The call will begin at 5:00 p.m. ET. The dial-in number is (877) 344-3890.  The conference passcode is Kforce.  The replay of the call will be available from 8:00 p.m. ET Monday, August 10, 2020 until August 17, 2020 by dialing (855) 859-2056, passcode 9977937.This call is being webcast by Shareholder.com and can be accessed at Kforce’s web site at http://investor.kforce.com.  The webcast replay will be available until August 17, 2020.About KforceKforce (Nasdaq: KFRC) is a professional staffing services and solutions firm that specializes in the areas of Technology and Finance...

WASHINGTON, July 08, 2020 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Daniel P. Wikel as a Senior Managing Director in the Turnaround & Restructuring practice within the firm’s Corporate Finance & Restructuring segment.Based in Chicago, Mr. Wikel advises clients on corporate turnarounds and restructurings, lender workout situations, transaction advisory services/business assessments and raising capital. He has significant experience managing middle-market and large bankruptcy cases and related matters, and his financial and operational expertise spans strategic planning, capital advisory or investment analysis and identifying revenue enhancements and cost improvements. Mr. Wikel has served as a financial advisor, interim manager and expert witness to companies across a variety...

COLUMBIA, Md., July 08, 2020 (GLOBE NEWSWIRE) — Rekor Systems, Inc. (NASDAQ:REKR) (“Rekor”) (“the Company”), a Maryland-based company providing real-time roadway intelligence through AI-driven decisions, announced today that it expected gross revenue to be above $2.6 million for the second quarter of 2020, which represents over 60% growth from the first quarter of 2020.Rekor’s recent divestiture of its TeamGlobal subsidiary has completed the final step in the Company’s announced change in strategic direction to sell lower margin assets and focus on Rekor’s core technology segment. Rekor also recently reached an agreement with its principal debt holders to exchange $14.6 million in aggregate principal of its senior secured promissory notes for 4,208,659 shares of the Company’s common stock and to modify the terms of the...

Anticipates $1.6 Million Net RevenuesSOUTH ORANGE, NJ, July 08, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced preliminary financial results for the quarter ended June 30, 2020.Net revenues for the quarter are expected to be $1.6 million, a decrease of approximately 33% compared to the quarter ended June 30, 2019. Nephros ended the quarter with approximately $7.0 million in cash on a consolidated basis.“The headwinds from COVID-19 stopped our four-year quarterly growth streak. We and our customers are adapting to the new normal, and we remain optimistic about our ability to return to our high growth rate path,” commented...

HOUSTON, July 08, 2020 (GLOBE NEWSWIRE) — Harvest Oil & Gas Corp. (OTCQX: HRST) (“Harvest” or the “Company”) announced today that a wholly-owned subsidiary has entered into a definitive agreement to sell its Appalachian Basin assets, which will represent substantially all of the assets of the Company, to an unaffiliated third party (“Buyer”) for consideration of $20.5 million, subject to customary purchase price adjustments. The consideration consists of $14.5 million of cash and a $6 million note.  The transaction is expected to close in August 2020 and has an effective date of July 1, 2020. The holders of a majority of the common stock of the Company have approved the transaction. The definitive agreement contains various representations, warranties, covenants and indemnification obligations of the Company and the Buyer that...

NEW YORK and CLEVELAND, July 08, 2020 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced recent updates on its clinical programs, highlighted by the restart of patient enrollment in the Company’s pivotal Phase 3 VIITAL™ study of EB-101, its autologous, gene-corrected cell therapy, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Enrollment in the VIITAL™ study at Stanford University Medical Center was paused in March 2020 in order to redirect healthcare resources to COVID-19 patients and to ensure the safety of study participants and site staff.“RDEB is a debilitating and life-threatening rare genetic disorder without an approved treatment option. Reinitiating enrollment in the VIITAL study is important for patients with RDEB and...

DALLAS, July 08, 2020 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented company focused on manufacturing and marketing aerosol delivery systems based on pressurized Metered Dose Inhaler (MDI) technology, announced today that it has delivered an initial 2,000 units under its previously announced 100,000 unit order.Rapid Therapeutic Science Laboratories, Inc. Chairman and CEO, Donal R. Schmidt, Jr. stated, “RTSL is moving forward on its first major wholesale contract. We have completed the first shipment totaling 2,000 units of our proprietary CBD/CBG formula under our white label order of 100,000 units we previously announced. These MDIs are currently being sold through doctors’ offices and in pharmacies across the United States. The initial lot of 2,000 was presold...

TORONTO, July 08, 2020 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) is pleased to announce the appointment of Mr. Tim Williams as Chief Operating Officer, effective July 13, 2020.Mr. Williams is a professional engineer with over 25 years of experience in mine construction and operation. Between 2011 and 2016 he served as VP Operations for Rio Alto Mining Inc. and subsequently Tahoe Resources Inc., during which time he was responsible for the construction, ramp-up and successful operation of the La Arena Gold Mine in Peru and the construction of the nearby Shahuindo Gold Mine. La Arena and Shahuindo are currently operated by Pan American Silver Corporation.Prior to Rio Alto, Mr. Williams served in a series of progressively more senior technical and project management roles including at the...

Patent coverage for CM24 now extends to the U.S. and the EUTEL AVIV, Israel, July 08, 2020 (GLOBE NEWSWIRE) — Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced receipt of a notification from the European Patent Office to grant a patent for Kitov’s application entitled “Humanized antibodies against CEACAM1.” The patent covers protein and DNA sequences pertaining to humanized antibodies capable of specific binding to human CEACAM1 molecules, including its lead monoclonal antibody, CM24, pharmaceutical compositions comprising these antibodies, as well as methods for their use in treating and diagnosing cancer and other conditions.Kitov is currently advancing preparations to initiate a Phase 1/2 clinical trial...